 <h1>Encorafenib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to encorafenib: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, encorafenib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking encorafenib:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding gums</li>
<li>bloating</li>
<li>chills</li>
<li>constipation</li>
<li>coughing up blood</li>
<li>dark urine</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, skin rash</li>
<li>hoarseness</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>indigestion</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>nosebleed</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>partial or slight paralysis of the face</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark-brown urine</li>
<li>redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>thickening of the skin</li>
<li>tightness in the chest</li>
<li>tingling of the hands and feet</li>
<li>ulceration of the skin</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bloody stools</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of encorafenib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>change in taste</li>
<li>difficulty in moving</li>
<li>dry skin</li>
<li>hair loss, thinning of hair</li>
<li>loss of taste</li>
<li>muscular pain, tenderness, wasting, or weakness</li>
<li>pain in the arms or legs</li>
<li>stomach pain</li>
<li>unsteadiness or awkwardness</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to encorafenib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (36%), hemorrhage (19%), leukopenia (13%), lymphopenia (13%), neutropenia (13%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (46%), myopathy (23%), pain in extremity (11%), myalgia, back pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Uveitis (e.g., iritis, iridocyclitis), visual impairment<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased alkaline phosphatase (35%), hyperglycemia (28%), hypermagnesemia (26%), hyponatremia (18%), decreased appetite<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased gamma glutamyl transferase (45%), increased ALT (29%), increased AST (27%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): New primary melanoma, cutaneous squamous cell carcinoma (cuSCC) including keratoacanthoma (KA), basal cell carcinoma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (30%), fatigue, peripheral edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Fatigue (46%), headache (22%), dizziness (15%), peripheral neuropathy (12%), intracranial hemorrhage in the setting of new or progressive brain metastases (sometimes fatal)</p>
<p><b>Common</b> (1% to 10%): Facial paresis, dysgeusia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (93%)</p>
<p><b>Common</b> (1% to 10%): Renal failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (e.g., pulmonary embolism, deep vein thrombosis, embolism, thrombophlebitis, thrombophlebitis superficial, thrombosis)</p>
<p><b>Uncommon</b> (0.1% to 1%): QTc interval prolongation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (53%), hyperkeratosis (49%), alopecia (38%), dry skin (26%), pruritus (21%), skin papilloma (e.g., keratoacanthoma, squamous cell carcinoma, lip squamous cell carcinoma, squamous cell carcinoma of skin), melanocytic nevus</p>
<p><b>Common</b> (1% to 10%): Panniculitis, new primary melanoma, basal cell carcinoma, skin papilloma, dermatitis acneiform, skin exfoliation, photosensitivity, panniculitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (41%), vomiting (30%), abdominal pain (28%), constipation (22%), diarrhea</p>
<p><b>Common</b> (1% to 10%): GI hemorrhage (including rectal hemorrhage), hematochezia, hemorrhoidal hemorrhage, pancreatitis, colitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is Braftovi used to treat?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about encorafenib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Encorafenib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Braftovi</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
<li>Melanoma, Metastatic</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to encorafenib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (36%), hemorrhage (19%), leukopenia (13%), lymphopenia (13%), neutropenia (13%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (46%), myopathy (23%), pain in extremity (11%), myalgia, back pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Uveitis (e.g., iritis, iridocyclitis), visual impairment<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased alkaline phosphatase (35%), hyperglycemia (28%), hypermagnesemia (26%), hyponatremia (18%), decreased appetite<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased gamma glutamyl transferase (45%), increased ALT (29%), increased AST (27%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): New primary melanoma, cutaneous squamous cell carcinoma (cuSCC) including keratoacanthoma (KA), basal cell carcinoma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (30%), fatigue, peripheral edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Fatigue (46%), headache (22%), dizziness (15%), peripheral neuropathy (12%), intracranial hemorrhage in the setting of new or progressive brain metastases (sometimes fatal)</p><p><b>Common</b> (1% to 10%): Facial paresis, dysgeusia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (93%)</p><p><b>Common</b> (1% to 10%): Renal failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (e.g., pulmonary embolism, deep vein thrombosis, embolism, thrombophlebitis, thrombophlebitis superficial, thrombosis)</p><p><b>Uncommon</b> (0.1% to 1%): QTc interval prolongation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (53%), hyperkeratosis (49%), alopecia (38%), dry skin (26%), pruritus (21%), skin papilloma (e.g., keratoacanthoma, squamous cell carcinoma, lip squamous cell carcinoma, squamous cell carcinoma of skin), melanocytic nevus</p><p><b>Common</b> (1% to 10%): Panniculitis, new primary melanoma, basal cell carcinoma, skin papilloma, dermatitis acneiform, skin exfoliation, photosensitivity, panniculitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (41%), vomiting (30%), abdominal pain (28%), constipation (22%), diarrhea</p><p><b>Common</b> (1% to 10%): GI hemorrhage (including rectal hemorrhage), hematochezia, hemorrhoidal hemorrhage, pancreatitis, colitis</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is Braftovi used to treat?</li>
</ul><h2>More about encorafenib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Encorafenib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
<li>Melanoma, Metastatic</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>